Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF

This webinar was held live on Wednesday 14th May 2025 at 12:00 pm BST.

Organised by the International Society of Cardiovascular Pharmacotherapy (ISCP), this free, 1-hour session provided healthcare professionals with a comprehensive overview of the evolving role of MRAs in HFmEF and HFpEF.

Non-steroidal MRAs, such as finerenone, have garnered particular attention due to their more selective mechanism of action, which may offer advantages over traditional steroidal MRAs like spironolactone and eplerenone. Data from pivotal trials, including FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, have provided compelling evidence that MRAs contribute to significant reductions in the combined endpoints of cardiovascular death and heart failure hospitalizations in patients with HFmEF and HFpEF.

This webinar provides a comprehensive overview of the evolving role of MRAs in HFmEF and HFpEF, highlighting:

The pathophysiology of mineralocorticoid receptor activation and its contribution to inflammation, fibrosis, and volume overload in heart failure.
Key clinical trials and meta-analyses that support the expanded use of MRAs beyond HFrEF.
Practical considerations for selecting appropriate patients for MRA therapy, with a focus on safety, renal function, and hyperkalemia risk mitigation.
Future directions in MRA research and its integration into evolving heart failure treatment guidelines.

This programme was supported by an unrestricted educational grant by Bayer.

Learning Objectives

✅Evaluate the pathophysiologic role of mineralocorticoid receptor activation in heart failure and its implications for HFmEF/HFpEF management.
✅Analyze the latest clinical evidence supporting the use of MRAs in HFmEF/HFpEF, including recent trial data and guideline recommendations.
✅Assess the safety profile of MRAs, including the risks of hyperkalemia, renal dysfunction, and other adverse effects in the HFmEF/HFpEF population.
✅Identify appropriate patients for MRA therapy, considering comorbid conditions, renal function, and serum potassium levels.
✅Develop individualized therapeutic plans incorporating MRAs into the broader management strategy for HFmEF/HFpEF, including combination therapy approaches and monitoring strategies.